XTL Biopharmaceuticals Ltd.
XTLB
$1.27
$0.043.25%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 194.00K | 145.00K | 157.00K | 238.00K | 219.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 200.00K | 151.00K | 163.00K | 251.00K | 225.00K |
| Operating Income | -200.00K | -151.00K | -163.00K | -251.00K | -225.00K |
| Income Before Tax | -284.00K | -215.00K | -364.00K | -919.00K | -748.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -284.00K | -215.00K | -364.00K | -919.00K | -748.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -284.00K | -215.00K | -364.00K | -919.00K | -748.00K |
| EBIT | -200.00K | -151.00K | -163.00K | -251.00K | -225.00K |
| EBITDA | -199.80K | -150.80K | -162.80K | -250.80K | -224.80K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | -- | -- | -- | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | -- | -- | -- | 0.00 |
| Average Basic Shares Outstanding | 544.91M | 544.91M | 544.91M | 544.91M | 544.91M |
| Average Diluted Shares Outstanding | 544.91M | 544.91M | 544.91M | 544.91M | 544.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
